This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Ardea Biosciences Inc. (working on small-molecule therapeutics for gout, HIV, and cancer) has netted $157.6mm through the follow-on offering of 9.8mm common shares (including the overallotment) at $17 each. Part of the proceeds will support ongoing Phase III trials of the company's lead candidate lesinurad for gout.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?